Twist Bioscience HQ
681 Gateway Blvd
South San Francisco, CA 94080
PI3K inhibition in combination with tamoxifen in patients with metastatic HR+/HER2- breast cancer: clinical and circulating tumor DNA results
PRODUCTS USED
ABSTRACT
To determine the safety and efficacy of taselisib, a selective PI3K-inhibitor, in combination with tamoxifen.POSEIDON is a phaseII, randomized, placebo-controlled trial conducted from June 2016 to March 2020. Eligible patients were refractory upon prior endocrine therapy. Prior treatment with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors and everolimus was allowed. Patients were randomized (1:1) to receive either taselisib (4mg) + tamoxifen (20mg) or placebo + tamoxifen. The primary endpoint of the trial was investigator-assessed progression-free survival (PFS) in the intention-to-treat (ITT) population (two-sided alpha 0.2, 90% power). Exploratory biomarker analysis with regards to prognosis and treatment resistance were conducted in circulating tumor (ct)DNA.POSEIDON met its primary endpoint, where patients treated with taselisib + tamoxifen had improved PFS compared to patients treated with placebo + tamoxifen in the ITT population (median PFS 4.8 months versus. 3.2 months; stratified hazard ratio 0.69, 80% CI 0.49-0.98, p=0.17). However, toxicity of taselisib was significant with diarrhea (40% any grade) as most common adverse event. Exploratory analyses indicated that high tumor fraction determined in ctDNA at baseline is associated with worse PFS and OS (p